ClinicalTrials.gg
RecruitingNCT06823466ASPERAUpdated Feb 20, 2025

Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

An observational study in Ischemic Stroke, Oral Anticoagulation and Atrial Fibrillation (AF), sponsored by University of L'Aquila. Recruiting at 47 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by University of L'Aquila · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.

Planned enrollment
22nd of 30
200 · median 550
Started
2025
with 10 others
Observational
30 of 81
11 open now
Primary completion
2027-02
later than 18 of 28 live
Registered
70th of 81
by date
Lead sponsor
4 of 81
University of L'Aquila

Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 22nd largest by planned enrollment of the 30 observational ones that give a count, is one of 11 that started in 2025, is one of 30 observational ones, reaches primary completion later than 18 of the 28 other live ones, and was the 70th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Ischemic Stroke with a site in Italy, or all of them as a file.
02

Study summary

The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or other cardioembolic arrhythmias and to characterize short and long-term outcomes associated with different secondary prevention strategies to prevent stroke recurrences. The ASPERA study is a multicenter, observational, both retrospective and prospective real-world study involving acute ischemic stroke patients occurring on oral anticoagulation. The study will encompass a retrospective (ASPERA-R) and prospective (ASPERA-P) data collection. Patient will be recruited consecutively at different emergency services and stroke units worldwide. University of L'Aquila (UnivAQ) will be in charge of study coordination, data analysis and management. The duration of ASPERA-R will be of 5-year from the study initiation of the study. Participating centers will be given a 6-month timeframe to enter retrospective data, commencing from the date of study approval.

ASPERA-P duration will be of 2 years of enrollment from the study approval and follow-up of 5 years. (study conclusion after 7 years of approval). Inclusion criteria will be: 1.Confirmed diagnosis of ischemic stroke. 2. Availability of at least one neuroimaging exam positive for ischemic lesion(s) consistent with patient symptoms. 3. Ongoing oral anticoagulation at the time of the index ischemic stroke. 4. Prior diagnosis of atrial fibrillation or other cardioembolic arrhythmias. 5. Written informed consent provided by the patient himself or by proxy. Patients with Symptoms not indicative of acute stroke, ongoing intravenous or subcutaneous anticoagulation at the time of stroke will be excluded. ASPERA-R: characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. The primary outcome will be: ASPERA-R : characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. ASPERA-P: risk of ischemic stroke recurrence of ischemic stroke cases occurring on oral anticoagulants across different secondary preventive strategies (i.e., maintaining the same type of oral anticoagulation versus switching to a different secondary prevention strategy) at 90 days, 1 and 5 years after the index stroke. Additionally, the study will aim to investigate the risk of safety events (hemorrhagic transformation, intracranial hemorrhage, other major bleeding events, any bleeding events, death due to any cause), risk of other major ischemic events (transient ischemic attack, myocardial infarction, death due to vascular causes) at each follow-up and to identify demographic, clinical and neuroimaging features of ischemic stroke recurrences.

03

Conditions studied

  • Ischemic Stroke
  • Oral Anticoagulation
  • Atrial Fibrillation (AF)
  • Outcome Assessment
  • Clinical Presentations

Keywords

  • Ischemic stroke
  • Oral anticoagulation
  • Atrial fibrillation
  • Direct oral anticoagulants
  • Vitamin k antagonists
  • Outcomes
  • Prognosis
  • Clinical characteristics
  • Secondary prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be enrolled from various recruiting sites worldwide. All consecutive ischemic stroke patients receiving oral anticoagulation therapy for atrial fibrillation or other cardioembolic arrhythmias at the time of the index stroke who meet the inclusion criteria will be eligible, regardless of hospitalization status. The decision to enroll a patient will be made by local investigators, who must ensure that each candidate meets the study's eligibility requirements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of the index ischemic stroke.
  • Confirmed diagnosis of ischemic stroke according to the World Health Organization (WHO) definition.
  • Availability of at least one neuroimaging exam (either a non-contrast computed tomography [NCCT] or magnetic resonance imaging [MRI] of the brain) demonstrating one or more ischemic lesions consistent with patient symptoms.
  • Ongoing oral anticoagulation at the time of the index ischemic stroke, defined as the last intake within 48 hours prior to stroke symptom onset for patients on direct oral anticoagulants (DOACs), or an (INR) of ≥1.5 in patients on vitamin K antagonists (VKAs), regardless of the time elapsed between the last intake and stroke symptom onset.
  • Prior diagnosis of AF or other cardioembolic arrhythmias.

Exclusion criteria

Exclusion Criteria:

  • Symptoms not indicative of acute stroke (i.e., syncope, tonic or clonic activity, dizziness alone, confusion and amnesia alone, chronic or subacute development of focal neurological deficit).
  • Ongoing parenteral (intravenous or subcutaneous) anticoagulation at the time of the index event, including bridging with heparin in patients initiating VKA.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • ASPERA-R

    Retrospectively enrolled schemic stroke patients on oral anticoagulants at the time of the index stroke followed up at hospital discharge and 90 days post-stroke

  • ASPERA-P

    Prospectively enrolled ischemic stroke patients on oral anticoagulants at the time of the index stroke followed up at 90 days, 1 year and 5 years post-stroke

06

What researchers measure

Primary outcomes

  1. ASPERA-R Primary Outcome Measure: Baseline demographic characteristics

    Baseline demographic characteristics of ischemic stroke cases occurring on oral anticoagulants: mean age (years), sex (proportion of males and females), ethnicity (proportion of non-Hispanic White, Hispanic White, Black, Asian, other ethnicities), mean weight (Kg), mean height (cm), median BMI

    Time frame: At the baseline (index ischemic stroke onset/hospital admission)

  2. ASPERA-R Primary Outcome Measure: Baseline clinical characteristics

    Baseline clinical characteristics: type of oral anticoagulation at the time of index ischemic stroke (proportion of patients on DOAC or VKA), ischemic stroke clinical severity (median National Insititue of Health Stroke Scale - NIHSS), type of clinical presentation (proportion of patients with anterior or posterior circulation stroke), competing stroke etiology (proportion of patients with large-artery-atherosclerosis or lacunar or other determined or undetermined etiology), risk factors (proportion of patients with hypertension, dyslipidemia, diabetes, history of prior stroke/transient ischemic attack, ischemic cardiopaty, peripheral artery disease, chronic kidney or liver failure), acute ischemic stroke treatment (proportion of patients who undergo intravenous thrombolysis or endovascular thrombectomy)

    Time frame: At the baseline (index ischemic stroke onset/hospital admission)

  3. ASPERA-R Primary Outcome Measure: Baseline Neuroimaging characteristics

    Baseline Neuroimaging characteristics: large vessel occlusion (proportion of patients with large vessel occlusion), site of large vessel occlusion (proportion of patients with anterior or middle or posterior cerebral arteries occlusion), degree of large vessel occlusion (according to the modified treatment in cerebral infarction - mTICI - score: from 0 - no perfusion - to 3 - complete perfusion), median number of new ischemic lesion(s) at neuroimaging, site of new ischemic lesion(s) at neuroimaging (anterior or posterior circulation, right or left hemisphere or bilateral), presence of hemorrhagic infarction at neuroimaging, degree of hemorrhagic infarction at neuroimaging (according to the Heidelberg classification system: Hemorrhagic Infarction - Small petechiae along the margins of the infarcted area or more confluent petechiae without space-occupying effect (HI2). Parenchymal Hematoma - A hematoma covering less (PH1) or more (PH2) than 30% of the infarcted area.

    Time frame: At the baseline (index ischemic stroke onset/hospital admission)

  4. ASPERA-P Primary Outcome Measure: New ischemic stroke or transient ischemic attack

    New ischemic stroke or transient ischemic attack (proportion of patients with new ischemic stroke or transient ischemic attack)

    Time frame: 90-day, 1-year and 5-year post-stroke

Secondary outcomes

  1. ASPERA-R Secondary Outcome Measure: All-cause mortality

    All-cause mortality (proportion of patients who died due to any cause)

    Time frame: Discharge and 90-day post-stroke

  2. ASPERA-R Secondary Outcome Measure: Vascular death

    Vascular death (death due to stroke, myocardial infarction, pulmonary embolism, sudden death or arrhythmias)

    Time frame: Discharge and 90-day post-stroke

  3. ASPERA-R Secondary Outcome Measure: New ischemic stroke or transient ischemic attack

    New ischemic stroke or transient ischemic attack (proportion of patients with new ischemic stroke or transient ischemic attack)

    Time frame: Discharge and 90-day post-stroke

  4. ASPERA-R Secondary Outcome Measure: Myocardial infarction

    Myocardial infarction (proportion of patients with any type of myocardial infarction)

    Time frame: Discharge and 90-day post-stroke

  5. ASPERA-R Secondary Outcome Measure: Moderate-to-severe bleeding events

    Moderate-to-severe bleeding events (proportion of patients with moderate-to-severe bleedings as defined according to the GUSTO bleeding classification): GUSTO severe or life-threatening bleeding is defined as either intracranial haemorrhage or bleeding resulting in haemodynamic compromise necessitating intervention. GUSTO moderate bleeding is defined as bleeding requiring transfusion, but not resulting in haemodynamic compromise.

    Time frame: Discharge and 90-day post-stroke

  6. ASPERA-R Secondary Outcome Measure: Intracranial hemorrhage

    Intracranial hemorrhage (any type of intracranial hemorrhage)

    Time frame: Discharge and 90-day post-stroke

  7. ASPERA-R Secondary Outcome Measure: Ordinal distribution of modified Rankin Scale scores

    Ordinal distribution of modified Rankin Scale scores (proportion of patients within each category of the modified Rankin Scale): Symptoms without any disability (score of 1), Symptoms with mild disability (score of 2), Symptoms with mild-to-moderate disability (score of 3), Symptoms with moderate-to-severe disability (score of 4), Symptoms with severe disability (score of 5), Death (score of 6)

    Time frame: Discharge and 90-day post-stroke

  8. ASPERA-P Secondary Outcome Measure: All-cause mortality

    All-cause mortality (proportion of patients who died due to any cause)

    Time frame: 90-day, 1-year and 5-year post-stroke

  9. ASPERA-P Secondary Outcome Measure: Vascular death

    Vascular death (death due to stroke, myocardial infarction, pulmonary embolism, sudden death or arrhythmias)

    Time frame: 90-day, 1-year and 5-year post-stroke

  10. ASPERA-P Secondary Outcome Measure: Myocardial infarction

    Myocardial infarction (proportion of patients with any type of myocardial infarction)

    Time frame: 90-day, 1-year and 5-year post-stroke

  11. ASPERA-P Secondary Outcome Measure: Intracranial Hemorrhage

    Intracranial hemorrhage (any type of intracranial hemorrhage)

    Time frame: 90-day, 1-year and 5-year post-stroke

  12. ASPERA-P Secondary Outcome Measure: Moderate-to-severe bleeding events

    Moderate-to-severe bleeding events (proportion of patients with moderate-to-severe bleedings as defined according to the GUSTO bleeding classification): GUSTO severe or life-threatening bleeding is defined as either intracranial haemorrhage or bleeding resulting in haemodynamic compromise necessitating intervention. GUSTO moderate bleeding is defined as bleeding requiring transfusion, but not resulting in haemodynamic compromise.

    Time frame: 90-day, 1-year and 5-year post-stroke

  13. ASPERA-P Secondary Outcome Measure: Minor bleeding events

    Minor bleeding events (proportion of patients with minor bleedings as defined according to the GUSTO bleeding classification): Any bleedings that is not intracranial haemorrhage or bleeding resulting in haemodynamic compromise necessitating intervention, or bleeding requiring transfusion.

    Time frame: 90-day, 1-year and 5-year post-stroke

  14. ASPERA-P Secondary Outcome Measure: Any bleeding events

    Any bleeding events (proportion of patients with any bleedings irrespective of their severity)

    Time frame: 90-day, 1-year and 5-year post-stroke

  15. ASPERA-P Secondary Outcome Measure: Ordinal modified Rankin Scale scores distribution

    Ordinal distribution of modified Rankin Scale scores (proportion of patients within each category of the modified Rankin Scale): Symptoms without any disability (score of 1), Symptoms with mild disability (score of 2), Symptoms with mild-to-moderate disability (score of 3), Symptoms with moderate-to-severe disability (score of 4), Symptoms with severe disability (score of 5), Death (score of 6)

    Time frame: 90-day, 1-year and 5-year post-stroke

07

Study locations

47 of 47 sites recruiting
  • Department of Neurology, Sveti Duh University Hospital
    Zagreb, 10000, Croatia
    Recruiting
    • Hrvoje Budincevic, MD, PhD · Contacthb@kbsd.hr
  • Copenhagen University Hospital, Bispebjerg Hospital
    Copenhagen, 2400, Denmark
    Recruiting
  • Neurology Department, Assiut University Hospitals
    Assiut, 71526, Egypt
    Recruiting
  • Neurology Department, Faculty of Medicine , Ain Shams University
    Cairo, 11566, Egypt
    Recruiting
  • Neurology Unit, Kobry Elkoba Medical Complex
    Cairo, 11799, Egypt
    Recruiting
  • Université Cote d'Azur UR2CA-URRIS, Unité Neurovasculaire, CHU Hôpital Pasteur 2
    Nice, 06001, France
    Recruiting
  • Department of Neurology, Charite, Berlin Germany and Center for Stroke Research (CSB)
    Berlin, 10117, Germany
    Recruiting
  • Department of Neurology, Martin-Luther-University of Halle-Wittenberg
    Halle (Saale), 06112, Germany
    Recruiting
  • Neurological Clinic, Marche Polytechnic University
    Ancona, 60126, Italy
    Recruiting
  • SC Neurologia, Stroke Unit, Ospedale di Venere
    Bari, 70131, Italy
    Recruiting
  • IRCCS Istituto delle Scienze Neurologiche
    Bologna, 40139, Italy
    Recruiting
  • SCA Neurologia, USL Umbria 1
    Città di Castello, 06012, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale Sant'Anna
    Ferrara, Italy
    Recruiting
  • SOD Stroke Unit, Azienda Ospedaliero Universitaria Careggi
    Florence, 50134, Italy
    Recruiting
  • Stroke Unit, Hospital Fabrizio Spazian
    Frosinone, 03100, Italy
    Recruiting
  • University of L'Aquila
    L'Aquila, 67100, Italy
    Recruiting
  • Neurology and Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
    Recruiting
  • Neurology and Stroke Unit, AORN Antonio Cardarelli
    Naples, 80131, Italy
    Recruiting
  • UOC Neurologia e Stroke Unit, AOOR. Villa Sofia - Cervello
    Palermo, Italy
    Recruiting
  • Department of Medicine and Surgery, University of Parma
    Parma, 43126, Italy
    Recruiting
  • Department of Emergency Neurology and Stroke Unit, IRCCS C. Mondino
    Pavia, 27100, Italy
    Recruiting
  • Medicina Interna e d'Urgenza - Stroke Unit, Azienda Ospedaliera di Perugia
    Perugia, 06132, Italy
    Recruiting
  • Department of Emergency Neurology and Stroke Unit, Pescara Hospital
    Pescara, 65124, Italy
    Recruiting
  • Department of Neuroscience, Neurology Unit, S.Maria delle Croci Hospital, AUSL Romagna
    Ravenna, 48124, Italy
    Recruiting
  • Neurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia
    Reggio Emilia, 42123, Italy
    Recruiting
  • UOSD Stroke Unit, Azienda Ospedaliera San Camillo Forlanini
    Rome, 00152, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli
    Rome, 00168, Italy
    Recruiting
  • UOC Neurologia, Ospedale Provinciale "Madonna del Soccorso"
    San Benedetto del Tronto, 63074, Italy
    Recruiting
  • UOC Stroke Unit, Emergency and Urgency Department, AOU Senese
    Siena, 53100, Italy
    Recruiting
  • ASL Abruzzo 4, G.Mazzini Hospital
    Teramo, 64100, Italy
    Recruiting
  • SOSD Stroke Unit, Department of Head, Neck, and Neuroscience, Udine University Hospital
    Udine, 33100, Italy
    Recruiting
  • Stroke Unit, Neurologia A, Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, 37126, Italy
    Recruiting
  • University Clinic of Neurology, University "Ss.Cyril and Methodius"-Faculty of Medicine
    Skopje, 1000, North Macedonia
    Recruiting
  • Department of Neurology, Jagiellonian University Medical College
    Krakow, 30-688, Poland
    Recruiting
  • Lisbon Central University Hospital - ULS São José and Faculdade de Medicina, Universidade de Lisboa
    Lisbon, 1649-028, Portugal
    Recruiting
  • Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
    Recruiting
  • Elias University Emergency Hospital, Carol Davila University of Medicine and Pharmacy
    Bucharest, 050474, Romania
    Recruiting
  • King Abdulaziz Medical City
    Riyadh, 11426, Saudi Arabia
    Recruiting
  • Vascular Neurology Division National Neuroscience Institute King Fahad Medical City
    Riyadh, 11525, Saudi Arabia
    Recruiting
  • Department of Neurology, Faculty of Medicine, P. J. Safarik University and University Hospital L. Pasteur
    Kosice, 040 11, Slovakia
    Recruiting
  • La Paz University Hospital, Universidad Autónoma de Madrid, IdiPAZ Research Institute
    Madrid, 28046, Spain
    Recruiting
  • Department of Medicine, University of Valladolid
    Valladolid, 47005, Spain
    Recruiting
  • University Teaching Hospital St. Gallen
    St. Gallen, 9007, Switzerland
    Recruiting
  • Southmead Hospital, North Bristol NHS Trust
    Bristol, UK BS10 5N, United Kingdom
    Recruiting
  • St George's University Hospitals NHS Foundation Trust
    London, UK SW17 0QT, United Kingdom
    Recruiting
  • Department of Brain Sciences, Imperial College London
    London, UK W12 0NN, United Kingdom
    Recruiting
  • Department of Stroke and Neuroscience, Charing Cross Hospital, Imperial College
    London, UK W6 8RF, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We plan to share individual clinical data collected in the study with other researchers upon reasonable request, in line with ethical guidelines and data protection regulations. Data will be de-identified to protect participant confidentiality.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: From the end of the ASPERA-P study (10/02/2029) up to 10 years (10/02/2039)

Access criteria: Access will be granted for purposes of replicating findings, conducting meta-analyses, or pursuing related research questions, subject to approval by the study's data governance committee and appropriate institutional review boards. Researchers will be required to sign data-sharing agreements to ensure proper use and compliance with confidentiality standards.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 24 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2025
First posted
Feb 12, 2025
StartActual
Feb 12, 2025
Primary completionEst.
Feb 12, 2027
CompletionEst.
Feb 12, 2031
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06823466
Lead sponsor
University of L'Aquila
Responsible party
Simona Sacco (Professor, University of L'Aquila) — Principal investigator
First posted
Feb 12, 2025
Start date
Feb 12, 2025
Primary completion
Feb 12, 2027 (estimated)
Completion
Feb 12, 2031 (estimated)
Last update
Feb 20, 2025

Study contacts

Simona Sacco, MD
Contact
simona.sacco@univaq.it
+39 0862433561
Matteo Foschi, MD
Contact
matteo.foschi@graduate.univaq.it
+39 3478929126

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion